"RegenRx"
Grant :
Center for Stem Cell and Regenerative Medicine
The Center for Stem Cell and Regenerative Medicine completed its second business spin-out with RegenRx incorporating the technologies developed by Marc Penn, M.D. Ph.D. at the Cleveland Clinic. The technology is based on the use of biological factors that induce endogenous stem cells to home and engraft into injured myocardial tissue. RegenRx currently has multiple term sheets from potential strategic partners are providing milestone-based funding for the company's pre-clinical and initial clinical development initiatives, and allow the company to establish operations. RegenRx has recently formed a new collaboration with Bioheart from Orlando, Florida to license developed technologies and establish an operational presence in Ohio. These activities will significantly improve biotechnological development in Cleveland and represents the largest Life Science license in the history of the Cleveland Clinic. The company is now seeking series A funding.
